Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 3/20 | 0.64 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.64 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.64 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.64 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.67 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | SRC | P12931 | 2/20 | 0.64 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.64 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.64 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.64 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | DPP4 | P27487 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.64 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.64 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.64 |
| ▸ | GAPDH | P04406 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL2033282 | 1.00 | P2RY2 (0.67) | P2RY2P2RY1SMN1; SMN2SRCP2RX1 | |
| Adenosine SCHEMBL2349814 | 1.00 | P2RY2 (0.67) | P2RY2P2RY1SMN1; SMN2SRCP2RX1 | |
| Adenosine SCHEMBL5476591 | 0.99 | P2RY2 (0.68) | P2RY2P2RY1SMN1; SMN2SRCP2RX1 | |
| SCHEMBL3164897 | 0.93 | P2RY2 (0.65) | P2RY2P2RY1SMN1; SMN2SRCP2RX1 | |
| Adenosine SCHEMBL28240733 | 0.91 | P2RY2 (0.80) | P2RY2P2RY1SMN1; SMN2SRCP2RX1 | |
| Adenosine SCHEMBL459770 | 0.91 | P2RY2 (0.80) | P2RY2P2RY1SMN1; SMN2SRCP2RX1 | |
| Adenosine SCHEMBL459996 | 0.91 | P2RY2 (0.80) | P2RY2P2RY1SMN1; SMN2SRCP2RX1 | |
| Adenosine SCHEMBL29362201 | 0.91 | P2RY2 (0.80) | P2RY2P2RY1SMN1; SMN2SRCP2RX1 | |
| Adenosine SCHEMBL9225148 | 0.90 | P2RY2 (0.79) | P2RY2P2RY1SMN1; SMN2SRCP2RX1 | |
| Adenosine SCHEMBL2210868 | 0.90 | P2RY2 (0.82) | P2RY2P2RY1SMN1; SMN2SRCP2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007020018-A1 | USE OF PURINERGIC AND PYRIMIDINERGIC RECEPTOR AGONISTS FOR DENDRITIC CELLS BASED IMMUNOTHERAPIES | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2007-02-22 | — | — | WO | claimed |
| US-6696425-B2 | STIMULATING TEAR SECRETION AND MUCIN PRODUCTION IN EYES OF A SUBJECT BY ADMINISTERING CERTAIN URIDINE, ADENINE, OR CYTIDINE TRIPHOSPHATES AS WELL AS OTHER DINUCLEOSIDE POLYPHOSPHATE COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | claimed |
| WO-2003028712-A2 | PURINERGIC AND PYRIMIDINERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF ACTIVATED CD4+ T LYMPHOCYTE-MEDIATED IMMUNE DISEASES | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2003-04-10 | — | — | WO | claimed |
| US-20020193340-A1 | Method of treating dry eye disease with purinergic receptor agonists | MERCK SHARP & DOHME CORP. | 2002-12-19 | — | — | US | claimed |
| EP-0200541-B1 | IMMUNOCHEMICAL METHOD AND ANALYTICAL COMPOSITION AND ELEMENT FOR DETERMINATION OF CREATINE KINASE-MB | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1990-10-03 | — | — | EP | claimed |
| EP-0200541-A2 | Immunochemical method and analytical composition and element for determination of creatine kinase-MB | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1986-11-05 | — | — | EP | claimed |
| JP-10215895-A | — | — | None | — | — | JP | disclosed |
| JP-5111396-A | — | — | None | — | — | JP | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-0755254-A1 | PREVENTION AND TREATMENT OF ISCHEMIA-REPERFUSION AND ENDOTOXIN-RELATED INJURY USING ADENOSINE AND PURINO RECEPTOR ANTAGONISTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0685561-A1 | REAGENT FOR ASSAYING CREATINE KINASE | IATRON LABORATORIES, INC. (JP) | 1995-12-06 | — | — | EP | disclosed |
| WO-1995026728-A1 | PREVENTION AND TREATMENT OF ISCHEMIA-REPERFUSION AND ENDOTOXIN-RELATED INJURY USING ADENOSINE AND PURINO RECEPTOR ANTAGONISTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1995-10-12 | — | — | WO | disclosed |
| JP-H05111396-A | METHOD FOR MEASURING ACTIVITY OF CREATINE KINASE AND REAGENT USED THEREFOR | ORIENTAL YEAST CO LTD | 1993-05-07 | — | — | JP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
| EP-0200541-B1 | IMMUNOCHEMICAL METHOD AND ANALYTICAL COMPOSITION AND ELEMENT FOR DETERMINATION OF CREATINE KINASE-MB | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1990-10-03 | — | — | EP | disclosed |
| EP-0200541-A2 | Immunochemical method and analytical composition and element for determination of creatine kinase-MB | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1986-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193340-A1 | Method of treating dry eye disease with purinergic receptor agonists | P2RY1, P2RY12, P2RY2 | ADORA1 35/4885ADORA3 43/4885ADORA2A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.